Catalent is considering acquisitions as it adds scale, drug delivery technologies and capacity in emerging markets.
The shift towards more strategic outsourcing and greater reliance on vendors is driving pursuit of scale, geographic reach and advanced capabilities at Catalent. To meet some of these goals Catalent made a $410m (€296m) move for Aptuit’s clinical trial supply assets and further deals are possible.
“If there’s an opportunity for us to pick up an inorganic acquisition at the right time and the right place we will certainly do that”, Scott Houlton, president, development and clinical services at Catalent, told Outsourcing-Pharma.
Houlton outlined areas of expansion at Catalent: “We will continue to invest in drug delivery technologies and also in scale. I think there are opportunities for us to look at the emerging markets, within China, India, other locations.”